<DOC>
	<DOCNO>NCT01299545</DOCNO>
	<brief_summary>Study Design &amp; Objectives : Multi-centre , non-interventional , open-label , non-comparative , prospective cohort study clinical follow-up 12 14 week . To determine performance RA-INF-Dx blood test intend aid identification patient rheumatoid arthritis unlikely show initial response infliximab methotrexate combination therapy evaluate accord EULAR response criterion . Ancillary study objective : To constitute biocollection sample associate clinical biological data collect inclusion evaluation visit .</brief_summary>
	<brief_title>Validation Study RA-INF-Dx , Multigene Molecular Test Used Predict Non-Response INfliximab Therapy</brief_title>
	<detailed_description>The RA-INF-Dx test non invasive vitro blood test intend aid identification patient RA unlikely show initial response infliximab methotrexate combination therapy . The RA-INF-Dx test indicate use patient : - 18 year age old , - Eligible first line biologic therapy infliximab . The RA-INF-Dx test indicate use rheumatologists biological basis guide infliximab treatment prior initiation .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Diagnosis Rheumatoid Arthritis 1 . Patient confirm Rheumatoid Arthritis accord American College Rheumatology ( ACR ) classification criterion . Disease Activity 2 . Patient DAS28 great 3.2 . Treatment 3 . Patient eligible first line TNFα block agent treatment infliximab accord `` Summary Product Characteristics '' , 4 . Patient refractory treatment least one classical DMARDs ( one MTX ) prescribe accord international recommendation , i.e . least 12 week maximal tolerate dose prior infliximab treatment dose must keep stable 4 week precede initiation infliximab therapy ( patient may include undergone washout period use cholestyramine equivalent subsequent leflunomide treatment ) , 5 . Use oral steroid ( ≤ 10mg/day prednisone equivalent dose another molecule ) and/or NSAIDs permit ; dos must keep stable 4 week precede initiation infliximab therapy , Other criterion 6 . Patient ( male female ) 18 year age old inclusion , 7 . Negative βHCG pregnancy test , appropriate accord patient 's age contraceptive method , 8 . Informed consent sign . 1 . Patient receive previous course biologic therapy ( TNF block agent , antiCD20 , antiCTLA4 , IL1 blocker , IL6 blocker molecule development ) , 2 . Patient non eligible infliximab therapy accord `` Summary Product Characteristics '' , 3 . Patient clinically significant , severe uncontrolled infectious disease , 4 . Patient symptom significant somatic psychiatric/mental illness , 5 . Patient autoimmune disease ( i.e . Inflammatory Bowel Diseases , Systemic Lupus Erythematosus , vasculitis , uncontrolled asthma , etc ... ) , 6 . Patient evidence cardiac , pulmonary , metabolic , renal , hepatic , gastrointestinal condition , , opinion investigator , may interfere study , 7 . Pregnancy , 8 . Patient participate clinical trial participate previous one within 10 week prior study entry .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>Anti TNF</keyword>
	<keyword>Infliximab</keyword>
	<keyword>Methotrexate</keyword>
	<keyword>DMARDs</keyword>
	<keyword>Gene expression biomarkers</keyword>
</DOC>